Why is GIPAM Global?

In September 2024, GIPAM expanded from a focus on Europe to repositioning as a global consultancy with the addition of Jason Simeone, PhD as the lead of GIPAM Inc., our US business. GIPAM’s full offerings now cover the EU and North America, with key services such as claims database studies available in other markets such as Latin/South America and Asia.

Why is GIPAM now a global company? The answer is simple: because increasingly, our clients’ focus is global, and your market access strategy and evidence generation activities must reflect that. Our expansion to the US means we can retain a local focus in important countries of interest such as Germany while enabling us to support you with key global activities, like integrated evidence generation planning and multi-country RWE studies.

There can be many advantages and efficiencies when executing your evidence generation plan from a global perspective. The alignment of key activities across markets provides you with the important ability to harmonize information like study selection criteria and outcome definitions across studies, reducing potential issues with regulatory and HTA submissions later. Budget savings can also occur through the use of study documents such as master protocols and study reports, as well as vendor project management costs. Most importantly, this approach can reduce the risk that evidence generation activities might overlap or even have remaining gaps, wasting time, budget, and potentially threatening your market access strategies.

GIPAM’s unique offerings complement this global approach to evidence generation and strategic market access. Our tool EVIGATOR makes evidence generation planning across markets simple, and resulting plans are coordinated across business units and markets. A GIPAM AI-based literature review tool called ANCHOR allows for the rapid screening and extraction of oncology trial publications published globally. We have extensive expertise navigating the dynamic data landscape in the US and other countries, and many clients have found our unbiased services around fit-for-purpose data feasibility, selection, and RWE study execution invaluable.

We are hard at work expanding our set of GIPAM tools that will support your evidence generation activities in the US, EU, and beyond. Stay tuned with us in 2025, there’s much more to come!